Pharmafile Logo
Pharmafocus logo
Advanced Search

pharma

Showing 15 posts of 2914 posts found.

Lilly’s pegilodecakin combo falls at Phase 3 in pancreatic cancer

October 17, 2019
Research and Development Cancer, Eli Lilly, FOLFOX, Pancreatic cancer, pegilodecakin, pharma

In disappointing news, Eli Lilly has revealed that pegilodecakin, in combination with the chemotherapy regimen FOLFOX (Folinic acid, Fluorouracil and …

News
_dsc6281_1

Medical cannabis: Riding the wave

October 16, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Kanabo research, medical cannabis, pharma

Following on from our previous piece from Mewburn Ellis on the history of social attitudes towards cannabis, Israel-based Kanabo Research …

Feature
shutterstock_273326141

Alexion to acquire Achillion Pharma for $930 million

October 16, 2019
Research and Development, Sales and Marketing Alexion, achillion, merger, pharma

Alexion has revealed it has signed a definitive agreement to acquire Achillion Pharmaceuticals in a deal valued at $930 million, …

News
eisa0008_web

China approves Eisai’s Fycompa for partial onset epileptic seizures

October 16, 2019
Research and Development, Sales and Marketing China, Eisai, Fycompa, epilepsy, pharma

Tokyo-headquartered firm Eisai has announced that its antiepileptic drug (AED) Fycompa (perampanel) has received approval from China’s National Medical Products …

News

FDA approves first and only transdermal patch for schizophrenia

October 16, 2019
Research and Development, Sales and Marketing FDA, Noven Pharma, Secuado, US, pharma, schizophrenia

Hisamitsu Pharmaceutical subsidiary Noven Pharmaceuticals has revealed the FDA approval of Secuado (asenapine) in adult schizophrenia patients, making it the …

News

Lilly’s Reyvow becomes first FDA-approved 5-HT1F receptor agonist for acute migraine

October 15, 2019
Manufacturing and Production, Sales and Marketing Eli Lilly, FDA, Reyvow, US, migraine, pharma

Eli Lilly has announced that the FDA has given the green light to Reyvow (lasmiditan) in the acute treatment of …

News
janssen_latest_logo_on_sign_closer

FDA approves Janssen’s Xarelto for blood clot prevention

October 15, 2019
Manufacturing and Production, Sales and Marketing FDA, Janssen, US, Xarelto, pharma, thromboembolism

Janssen’s Xarelto (rivaroxaban) has secured FDA approval for the prevention of venous thromboembolism (VTE), or blood clots, in hospitalised acutely …

News
_dsc6538

Medical cannabis: On to greener pastures?

October 14, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing medical cannabis, medicinal cannabis, pharma

In the first of three articles on the topic, Callum McGuinn, Associate and European Patent Attorney at Mewburn Ellis, explores …

Feature

Pfizer reveals strong Phase 3 data for abrocitinib in atopic dermatitis

October 14, 2019
Research and Development, Sales and Marketing Pfizer, abrocitinib, atopic dermatitis, pharma

Pfizer confirmed over the weekend that its oral Janus kinase 1 (JAK1) inhibitor abrocitinib met all of its co-primary and …

News
roche__tree

Roche’s Phase 3 Pemphix trial smashes primary endpoint for pemphigus vulgaris

October 14, 2019
Research and Development, Sales and Marketing MabThera, Rituxan, Roche, pharma

Roche has revealed new Phase 3 data demonstrating that its MabThera/Rituxan (rituximab) therapy Pemphix met its primary endpoint in the …

News
jim_greenwood

Biotechnology Innovation Organization Chief to step down after US 2020 elections

October 11, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Biotechnology Innovation Organization, US, biotech, pharma

The Biotechnology Innovation Organization (BIO), the largest trade body representing the world’s biotechnology industry, has revealed that its President and …

News

Clovis Oncology’s Rubraca now available via the Cancer Drugs Fund for ovarian, peritoneal, fallopian tube cancer

October 11, 2019
Medical Communications, Sales and Marketing Cancer, Clovis Oncology, NHS, NICE, Rubraca, fallopian tube cancer, ovarian cancer, peritoneal cancer, pharma

NICE has announced it has made an about-face on its earlier ruling for Clovis Oncology’s Rubraca (rucaparib), revealing that the …

News
novartis_side_building

Novartis’ Cosentyx provides sustained resolution of psoriatic arthritis symptoms up to 2 years, data shows

October 10, 2019
Research and Development Cosentyx, Novartis, pharma, psoriatic arthritis

Novartis has unveiled new findings for Cosentyx (secukinumab) which show that the therapy generated “rapid and sustained resolution” of signs …

News
lung_ambition_alliance

The Lung Ambition Alliance: Stronger together

October 9, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Cancer, Lung Ambition Alliance, lung cancer, pharma

Following our piece by AstraZeneca’s Patrick Connor introducing the Lung Ambition Alliance, a new cross-functional collaboration which aims to double …

Feature

FDA approves Pfenex’s osteoarthritis drug for patients at high risk of fracture

October 9, 2019
Research and Development, Sales and Marketing FDA, Pfenex, osteoporosis, pharma

The FDA has awarded US approval to Pfenex’s drug PF708, it has emerged, as a treatment for osteoporosis in certain …

News
The Gateway to Local Adoption Series

Latest content

Rhythm AI’s STAR Apollo system receives FDA clearance for atrial fibrillation

February 12, 2026

iOrganBio appoints Karol Jarzabek as Chief Operating Officer

February 12, 2026

Ensera Design expands UK leadership team with new senior appointments

February 11, 2026

Infinitopes announces $15.4m in additional seed funding to advance cancer vaccine

February 11, 2026

Angelini Pharma appoints Roberto Scrivo as Chief of External Affairs, Communication and Sustainability Officer

February 10, 2026